Everfront Biotech to Present Updated Cerebraca® Wafer Clinical Trial Results at the SNO 2025 Annual Meeting
Date: November 17, 2025
At the Society for Neuro-Oncology (SNO) Annual Meeting in Hawaii, USA, on November 19, 2025, Everfront Biotech will present the latest updated results from its Phase I/IIa clinical trial of Cerebraca® Wafer for the treatment of Recurrent Glioblastoma (GBM), and will also outline its plans for the upcoming Phase IIb/III clinical trial.
[TAIPEI, TAIWAN] – November 11, 2025 – Everfront Biotech, Inc. today announced its selection to present key research findings in an e-Poster format at the Society for Neuro-Oncology (SNO) 2025 Annual Meeting. The conference will be held from November 19 to 23, 2025, in Hawaii, USA, and stands as the most prestigious annual academic event in the global neuro-oncology community.
Premier Global Platform: Focusing on Neuro-Oncology Frontiers
The SNO Annual Meeting brings together scientists, clinicians, community physicians, health professionals, trainees, patient advocates, and industry representatives from around the world, providing a high-visibility international platform for exchange. The conference is dedicated to presenting the most cutting-edge basic and clinical research in neuro-oncology, featuring plenary sessions led by global leaders, invited lectures, symposia, and workshops, fostering rich academic exchange and international collaboration for all attendees.
Everfront Biotech to Showcase Key Cerebraca® Wafer Data
Everfront Biotech has been selected for a Poster Presentation at the conference. The company will unveil the latest updated results from its Phase I/IIa clinical trial of Cerebraca® Wafer for the treatment of Recurrent Glioblastoma (GBM), and will also outline its plans for the upcoming Phase IIb/III clinical trial.
Cerebraca® Wafer is one of Everfront Biotech’s core products, focused on addressing multiple challenges in the treatment of malignant brain tumors. The clinical data to be presented at SNO 2025 is vital for evaluating Cerebraca® Wafer’s safety and preliminary efficacy, and represents the drug’s imminent progression from early development toward more critical clinical trials, marking a new chapter in the product pipeline’s development.
Online Abstract Link: https://virtual.oxfordabstracts.com/event/74646/submission/637
Product Highlights of Cerebraca® Wafer:
Cerebraca® Wafer is a revolutionary implantable drug designed for the localized treatment of malignant brain tumors. Developed using multiple patented innovations, the product aims to solve critical challenges in brain cancer therapy—such as chemoresistance, high cancer stem cell content, and tumor recurrence.
Cerebraca® Wafer works by targeting receptor tyrosine kinase (RTK) signaling networks, modulating tumor resistance, and counteracting PD-L1-mediated immune evasion, a common barrier to effective treatment. In Phase I/IIa trials, no drug-related adverse effects were reported. Recurrent GBM patients showed a median overall survival of 15.7 months, with RTK-high subgroups reaching up to 26.2 months—a significant improvement over the current standard of care (6–9 months).
Everfront Biotech is actively seeking strategic partnerships and licensing opportunities to co-develop this promising therapy and extend its benefits to more patients worldwide.
Introduction to Everfront Biotech Inc.:
Everfront Biotech Inc. was founded in 2010, with a focus on research and development of new drugs, specifically the screening and further development of potential small molecules for clinical study. The company’s team is responsible for all aspects of product development, from front-end potential product development to pre-clinical research, chemistry manufacturing and controls (CMC), clinical trial submissions, and clinical trial planning and execution. To date, the Everfront Biotech team has successfully applied three clinical trials: Cerebraca® Wafer (for malignant brain tumors), HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer), which have been approved for IND applications in both the United States and Taiwan.
Everfront Biotech’s new drug development is in line with national policies, and the Cerebraca® Wafer and HK-001 products were granted the certifications of biotech and new drug in 2016. The company has received the government subsidies in three science and technology projects as of 2022 from the Ministry of Economic Affairs.
